Summit Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 3.18, 73.84, 702.45, 2265.35, 3765.77 ], "ebit_estimate": [ -884.91, -962.07, -650.15, 327.15, 1779.77 ], "ebitda_estimate": [ -891.93, -820.78, -599.75, null, null ], "net_income_estimate": [ -854.62, -910.21, -698.44, 2.64, 1625.79 ], "per_share_eps_estimate": [ -1.12, -1.14, -0.91, 0.22, 1.64 ], "eps_nri_estimate": [ -1.1, -1.1, -0.79, 0.1, 1.99 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.1, 0.01, 0.56, null, null ], "pretax_income_estimate": [ -856.09, -927.31, -593.4, 351.69, 1797.5 ], "operating_cash_flow_per_share_estimate": [ -0.7, -0.49, 0.56, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -146.87, -555.93, -24.35, null, null ], "gross_margin_estimate": [ 80, 84, 86.75, 85, 82 ], "operating_cash_flow_estimate": [ -542.82, -379.97, 434.26, null, null ], "pettm_estimate": [ 0, 0, 0, 69.63, 9.3 ], "long_term_growth_rate_mean": 16.66, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 12.78, "future_eps_nri_estimate_growth": 16.66, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 13.75, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 11.69, "future_pretax_income_estimate_growth": 15.76, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, 0.08, 3.46, 9.3, 13.5, 17.68, 25.13 ], "ebit_estimate": [ -196.49, -206.36, -238.48, -207.32, -210.69, -215.02, -216.49 ], "ebitda_estimate": [ -169.98, -173.26, -175.94, null, null, null, null ], "net_income_estimate": [ -201.46, -211.19, -247.25, -204.88, -208.86, -213.32, -215.4 ], "per_share_eps_estimate": [ -0.27, -0.28, -0.34, -0.32, -0.32, -0.33, -0.35 ], "eps_nri_estimate": [ -0.28, -0.28, -0.33, -0.28, -0.28, -0.29, -0.3 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -192.42, -202.95, -239.61, -204.88, -208.86, -213.32, -215.4 ], "operating_cash_flow_per_share_estimate": [ -0.17, -0.19, -0.21, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -146.77, -210.22, -181.85, null, null, null, null ], "gross_margin_estimate": [ null, 80, 80, 81, 81, 81, 81 ], "operating_cash_flow_estimate": [ -131.83, -147.34, -162.85, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 16.66, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 12.78, "future_eps_nri_estimate_growth": 16.66, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 13.75, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 11.69, "future_pretax_income_estimate_growth": 15.76, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }